Liquidia Technologies, a privately held biopharmaceutical company
developing particle-based vaccines and therapeutics, today announced it
has completed a $20 million round of Series C financing. Canaan Partners
led the Series C round, which also included Pappas Ventures and
Morningside Venture Investments Limited as new investors. Previous
investors, including New Enterprise Associates and Firelake Capital,
also participated in the financing round. The funds will be used to
accelerate Liquidia’s lead vaccine candidate through initial clinical
evaluation and expand development of particle-based solutions for siRNA
delivery and inhaled therapeutics.
“We are
pleased to attract excellent investors and a tremendous level of
interest in the PRINT® platform as a result of our progress.”
"This additional funding provides further validation of Liquidia’s
leadership in the development of particle-based vaccines and
therapeutics," said Neal Fowler, CEO of Liquidia Technologies. "We are
pleased to attract excellent investors and a tremendous level of
interest in the PRINT® platform as a result of our progress.”
As part of the Series C financing, Stephen Bloch, MD, a General Partner
with Canaan Partners, and Isaac Cheng, MD, with Morningside Technology
Advisory LLC, have joined the Liquidia Board of Directors.
“We are very excited to support the development of Liquidia’s initial
product and help fuel the next stage of growth for Liquidia,” said Dr.
Bloch, of Canaan Partners. “The company’s PRINT platform technology
represents a paradigm shift for the design and development of innovative
vaccines and therapeutics, opening the doors to unprecedented control
over drug product design.”
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare